Frankfurt
07.01.26 | 08:11
2,842 Euro
-0,14 % -0,004
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,940 | 3,114 | 07:04 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Wedbush initiates coverage on Hansa Biopharma stock with Outperform rating | 1 | Investing.com | ||
| 19.12.25 | Hansa Biopharma AB: Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation | 535 | PR Newswire | The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patientsImlifidase is an enzyme that rapidly and efficiently cleaves all types... ► Artikel lesen | |
| 19.12.25 | HANSA BIOPHARMA AB: Hansa Biopharma presenting at 44th Annual J.P. Morgan Healthcare Conference | 2 | Cision News | ||
| 16.12.25 | Hansa Biopharma AB: Hansa provides update on Pivotal Phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease | 200 | GlobeNewswire (Europe) | Lund, Sweden, 16 December 2025. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that GOOD-IDES-02, a global pivotal Phase 3 trial in anti-glomerular basement membrane (anti-GBM)... ► Artikel lesen | |
| 15.12.25 | Hansa Biopharma AB: Hansa Biopharma announce changes to strengthen European and International organisation | 139 | GlobeNewswire (Europe) | Lund, Sweden, December 15, 2025. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced a reorganization of its European and International Commercial and Medical Affairs operations, effective... ► Artikel lesen | |
| 13.11.25 | HANSA BIOPHARMA AB: Hansa Biopharma presenting at Jefferies Global Healthcare Conference and DNB Carnegie's 16th Annual Nordic Healthcare Conference | 2 | Cision News | ||
| HANSA BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 05.11.25 | HANSA BIOPHARMA AB: Hansa at Truist Securities, Stifel, and SEB Healthcare conferences | 5 | Cision News | ||
| 30.10.25 | Hansa Biopharma GAAP EPS of -SEK1.75, revenue of SEK 30.8M | 3 | Seeking Alpha | ||
| 30.10.25 | Hansa Biopharma AB: Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results | 345 | PR Newswire | Imlifidase successfully met primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation.
First clinical data supports imlifidase ability... ► Artikel lesen | |
| 29.10.25 | Hansa Biopharma AB: Hansa hosts call with distinguished transplant surgeons: Insights on clinical practice and imlifidase Phase 3 Results | 558 | PR Newswire | LUND, Sweden, Oct. 29, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that it will host a virtual event featuring two distinguished transplant... ► Artikel lesen | |
| 29.10.25 | Jefferies backs Hansa Biopharma on U.S. launch hopes after trial success | 5 | Investing.com | ||
| 10.10.25 | HANSA BIOPHARMA AB: Data from GNT-018-IDES trial supports feasibility of imlifidase as pretreatment in gene therapy treatment for patients with Crigler-Najjar syndrome who are immune to AAV | 2 | Cision News | ||
| 08.10.25 | HANSA BIOPHARMA AB: Hansa Biopharma to host Q3 2025 interim results conference call | 1 | Cision News | ||
| 07.10.25 | HANSA BIOPHARMA AB: Hansa Biopharma participating in Optimum's 17th Annual Healthcare Investor Conference and at Nordic Life Science Days 2025 | 1 | Cision News | ||
| 26.09.25 | HANSA BIOPHARMA AB: Genethon to present preliminary efficacy and safety data from Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 at ESGCT congress 2025 | 4 | Cision News | ||
| 24.09.25 | Hansa Biopharma AB: Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation | 193 | GlobeNewswire (Europe) | At 12 months, mean eGFR was 51.5 mL/min/1.73m2 in the imlifidase arm versus 19.3 mL/min/1.73m2 in the control arm with a statistically significant and clinically meaningful difference of 32.2 mL/min/1.73m2... ► Artikel lesen | |
| 15.09.25 | HANSA BIOPHARMA AB: Hansa Biopharma Presenting at the Pareto 16 Annual Healthcare Conference | 4 | Cision News | ||
| 04.09.25 | HANSA BIOPHARMA AB: Hansa Biopharma to Participate in H.C. Wainwright 27th Annual Global Investment Conference | 1 | Cision News | ||
| 02.09.25 | Hansa Biopharma AB: Bulletin from the Extraordinary General Meeting in Hansa Biopharma AB (publ) | 244 | GlobeNewswire (Europe) | Lund, Sweden, September 2, 2025. Hansa Biopharma AB (publ), "Hansa" (Nasdaq Stockholm: HNSA), has today on September 2, 2025 held its Extraordinary General Meeting. The Extraordinary General Meeting... ► Artikel lesen | |
| 07.08.25 | Notice to Extraordinary General Meeting in Hansa Biopharma AB (publ) | 2 | Cision News |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 85,70 | -0,06 % | BYD gegen Tesla! KI-Profiteure BioNTech und Rio Tinto Partner Aspermont! Aktien für 2026? | Paukenschlag kurz vor Silvester! BYD hat Tesla vom E-Auto-Thron gestoßen. Die Chinesen sind jetzt auch Weltmarktführer bei rein elektrischen Fahrzeugen. Doch die Aktie hat 2025 klar enttäuscht. Ein... ► Artikel lesen | |
| EVOTEC | 6,290 | +8,86 % | EQS-News: Evotec SE: Evotec ernennt Dr. Sarah Fakih als EVP, Leiterin Global Communications und Investor Relations | EQS-News: Evotec SE
/ Schlagwort(e): Personalie
Evotec ernennt Dr. Sarah Fakih als EVP, Leiterin Global Communications und Investor Relations
01.01.2026 / 07:30 CET/CEST
Für... ► Artikel lesen | |
| CUREVAC | 3,930 | -0,05 % | XFRA 5CV: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCUREVAC N.V. O.N.... ► Artikel lesen | |
| MODERNA | 30,760 | +0,05 % | MODERNA: Heute ein Exot dank Impfstoff-Fortschritt. | Das Biotech-Unternehmen schafft heute eine Performance von aktuell + 9,7 %. Abgesehen vom zweiten "Exoten" AXON (+ 6,0 %), wird das Feld Top 10 klar von Halbleiter-Werten dominiert. Für den Antrieb... ► Artikel lesen | |
| NOVAVAX | 6,591 | +1,09 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,950 | -0,67 % | HEIDELBERG PHARMA AG zeigt fundamentale Stärke | ||
| CRISPR THERAPEUTICS | 50,000 | +0,40 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112) in Autoimmune Diseases and Hematologic Malignancies | -Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the... ► Artikel lesen | |
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 695,80 | 0,00 % | Regeneron Just Moved From Underperform To Buy - Here's Why | ||
| INOVIO PHARMACEUTICALS | 1,450 | +0,69 % | INOVIO Pharmaceuticals, Inc.: FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) | PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,398 | +1,79 % | Revolutionäre Fortschritte: BioTech-Ideen für 2026! Bayer, Novo Nordisk, BioNxt, Vidac, BioNTech und Evotec! | Trotz eines schwierigen Umfelds 2025 bleibt der Biotech-Sektor fundamental attraktiv, da der medizinische Fortschritt nicht zum Stillstand kommt. Der rasante Einsatz von Künstlicher Intelligenz und... ► Artikel lesen | |
| OCUGEN | 1,366 | 0,00 % | Ocugen Provides Business Update with Third Quarter 2025 Financial Results | Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA)... ► Artikel lesen | |
| MAINZ BIOMED | 1,260 | 0,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed gibt Rückblick auf die Highlights des Jahres 2025 | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed gibt Rückblick auf die Highlights des Jahres 2025
05.01.2026 / 14:15 CET/CEST
Für den... ► Artikel lesen | |
| INFLARX | 1,000 | -3,15 % | Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? | LONDON (dpa-AFX) - Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Tivic Acquires Scorpius Manufacturing Assets And Secures More Than $90 Million Financing |
HANSA BIOPHARMA AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,842 Euro und damit -0,14 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HANSA BIOPHARMA AB finden Sie auf Wallstreet Online.